# Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

Xavier Ayrignac, Emmanuelle Le Bars, Claire Duflos, Christophe Hirtz, Aleksandra Maleska Maceski, Clarisse Carra-Dallière, Mahmoud Charif, Frédéric Pinna, Pauline Prin, Nicolas Menjot de Champfleur, et al.

► To cite this version:

Xavier Ayrignac, Emmanuelle Le Bars, Claire Duflos, Christophe Hirtz, Aleksandra Maleska Maceski, et al.. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Scientific Reports, 2020, 10 (1), pp.10923. 10.1038/s41598-020-67934-2 . inserm-02904593

HAL Id: inserm-02904593

https://inserm.hal.science/inserm-02904593

Submitted on 22 Jul 2020

**HAL** is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

OPEN

# Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

Xavier Ayrignac<fnref n="1" />✉, Emmanuelle Le Bars²,³,⁴, Claire Duflos⁵, Christophe Hirtz⁶,⁷, Aleksandra Maleska Maceski⁶,⁷, Clarisse Carra-Dallière<fnref n="1" />, Mahmoud Charif<fnref n="1" />, Frédéric Pinna<fnref n="1" />, Pauline Prin<fnref n="1" />, Nicolas Menjot de Champfleur²,³,⁴, Jérémy Deverdun²,³,⁴, Tobias Kober⁸,⁹,¹⁰, Bénédicte Marechal⁸,⁹,¹⁰, Mario Joao Fartaria⁸,⁹,¹⁰, Ricardo Corredor Jerez⁸,⁹,¹⁰, Pierre Labauge<fnref n="1" /> & Sylvain Lehmann⁶,⁷

Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to better differentiate disease activity from disease progression. The aim of our study was to assess serum glial fibrillary acid protein (s-GFAP) and neurofilament light chain (s-NfL) in a cohort of 129 multiple sclerosis (MS) patients. Eighteen primary progressive multiple sclerosis (PPMS) and 111 relapsing remitting MS (RRMS) were included. We showed that these 2 biomarkers were significantly correlated with each other (R = 0.72, *p* < 0.001). Moreover, both biomarkers were higher in PPMS than in RRMS even if multivariate analysis only confirmed this difference for s-GFAP (130.3 ± 72.8 pg/ml vs 83.4 ± 41.1 pg/ml, *p* = 0.008). Finally, s-GFAP was correlated with white matter lesion load and inversely correlated with WM and GM volume. Our results seem to confirm the added value of s-GFAP in the context of multiple sclerosis.

Multiple sclerosis (MS) is a complex autoimmune neurological disease<fnref n="1" />. Despite progresses in the management of MS, reliable and easy-to-use biomarkers are needed to accurately identify patients at risk of future disease progression².

The recent development of highly sensitive immunoassay platforms has enabled the measurement in the serum of several biomarkers of interest in MS. Notably, serum neurofilament light chain (s-NfL) is correlated with disease activity, treatment response, risk of disease progression and MRI markers of disease activity/sever-ity³⁻⁸. Serum Glial Fibrillary Acid Protein (s-GFAP), an intermediate astrocytes cytoskeletal protein, has been only more recently shown to be higher in progressive MS than in RRMS and correlate with disability⁹⁻¹¹.

Our aim was to evaluate s-GFAP value in an exploratory MS cohort and to assess its potential added value in combination with s-NfL value.

<footnote n="1">¹Département de Neurologie, CRC sclérose en Plaques, CHU Montpellier, Univ Montpellier, INSERM, 80 Av Augustin Fliche, 34295 Montpellier, France. ²Department of Neuroradiology, Montpellier University Hospital Center, Montpellier, France. ³I2FH, Institut D'Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, CHRU de Montpellier, Montpellier, France. ⁴Laboratoire Charles Coulomb, CNRS UMR 5221, Université de Montpellier, Montpellier, France. ⁵Economic Evaluation Unit, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France. ⁶Laboratoire de Biochimie-Protéomique Clinique, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France. ⁷IRB, Institute of Regenerative Medicine and Biotherapy IRMB - INSERM, Montpellier, France. ⁸Advanced Clinical Imaging Technology, Siemens Healthcare, Lausanne, Switzerland. ⁹Department of Radiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. ¹⁰LTS5, École Polytechnique, Lausanne, Switzerland. ✉email: xavier.ayrignac@yahoo.fr</footnote>
## Methods

Patients were recruited in a single-centre cross-sectional study. MS diagnosis was done retrospectively according to the 2017 McDonald criteria¹². All the MS patients with serum sampled between January 2016 and December 2018 were included in the study. Patients had either relapsing–remitting MS (RRMS) or primary progressive MS (PPMS). The following variable were analysed: gender, age, disease duration, Expanded Disability Status Scale (EDSS), disease-modifying therapy, and existence of a clinical relapse in the past 3 months before blood sampling.

Blood samples (and CSF samples for 37 patients) were collected, and serum was stored at -80 °C. Samples were submitted to only one freeze thaw cycle and were stored less than 2 years before use. GFAP and NfL were measured using the Neurology-4-plex assay (Simoa technology, Quanterix Corporation, Lexington, MA, USA). The limit of quantification for NfL and GFAP were 0.24 pg/mL and 0.47 pg/mL, respectively. Sample results show low inter assay variation with coefficient of variation less than 12% and 5% for NfL and GFAP. Quality controls provided in the kit whit low and high concentration of NfL and GFAP also showed inter and intra assay variations, with CV lower than 10% and 4%, respectively.

MRI analysis of 50 patients was obtained for 36 patients with a 3T Skyra Siemens scanner (VE11C software version, 32 element head Coil) and for 14 patients with a 1,5T Aera Siemens scanner (VE11C software version, 32 element head coil). Only patients with no gadolinium enhancement were analysed. The acquisition protocol included a sagittal 3D Fluid-Attenuated Inversion Recovery (FLAIR) and sagittal T1-weighted magnetization-prepared rapid 3D gradient-echo (MPRAGE): 3D-T1 parameters 1,5T/3T: TR 2,400/2300 ms TE 3,47/2,98 ms, TI 1,000/900 ms, θ=8°/9°, BW 180/240 Hz/Px, voxel size = 1.25 × 1.25 × 1.25/1 × 1 × 1.2 mm; 3D-FLAIR parameters 1,5T/3T: TR 5,000/5000 ms TE 336/384 ms, TI 1,800/1,800 ms, Factor Turbo 222/278, BW 590/751 Hz/Px, voxel size = 1.09 × 1.09 × 1.2 mm/0.9 × 0.9 × 0.9 mm. A quality check based on image and lesion segmentation analysis was performed by two imaging experts (ELB and MJF). From this analysis 5 out of 50 cases were excluded from our dataset due to (1) missing data (ie, one of the contrasts was not acquired), (2) poor image quality due to noise or artefacts, (3) low lesion segmentation quality (inconsistent results from the automated segmentation).

The White Matter Hyperintensity load (WMHL) volume was computed on 3D-FLAIR using automated prototype software initially designed for Multiple Sclerosis lesion segmentation¹³. This method consists of two main steps: (1) pre-processing, where the images are aligned, skull-striped, corrected for bias field and intensity-normalized; and (2) lesion segmentation, performed by a supervised classifier based on k-nearest-neighbor (k-NN) algorithm that outputs a lesion probability map, ie, each voxel is labeled with a value representing the probability of containing lesion tissue¹⁴. Spatial constraints to estimate realistic concentration maps of healthy tissues (White Matter, Grey Matter, Cerebrospinal Fluid), and pathological brain tissue were included. These probability maps are used to directly compute lesion volumes. In addition, this algorithm proposes to automatically assess WMHL while taking into account the mixing of healthy and lesional tissue in the image voxels due to partial volume effects¹⁵.

Owing to their intensity on 3DT1, white matter lesions may be erroneously segmented as gray matter. Thus, areas identified as WMHL on 3DFLAIR and responsible of hypointense lesions on 3DT1 were filled by the mean global WM intensity of the patient. Resulting images were then segmented using the DARTEL approach in SPM12 (Statistical Parametric Mapping; the Wellcome Trust Center for Neuroimaging, UK). Finally, WFU pickatlas lobar template was warped to subject space to estimate the regional gray matter (GM), white matter (WM) and WMHL volumes.

Statistical analyses were performed using SAS. Biomarkers were log-transformed. After that, correlation between quantitative variables was measured using Pearson's rho, and comparison of biomarkers between groups was tested using Student's t-test. Disease duration was not transformed, and its correlation with biomarkers was measured using Spearman's rho. The adjusted association between each biomarker and 1/the type of disease (PPMS or RRMS), and 2/the presence of recent relapse in patients with RRMS, was assessed using logistic regressions. We tested potential confounding of known confusion factors (age, disease duration), and selected variables with significant p-value in the multivariable model. All analyses are considered significant for *p* < 0.05.

All patients gave written informed consent. Local Ethic committee of the Montpellier University Center approved the study (2019_IRB-MTP_02-15). Our study was performed in accordance with the Current French ethical standards.

## Results

One-hundred-twenty-nine patients (97 females, 111 RRMS and 18 PPMS) were recruited. Main characteristics of the patients are disclosed in the Table 1.

S-GFAP and s-NfL levels were correlated with each other (Fig. 1A) and, for each biomarker, serum levels correlated with CSF levels (respectively R = 0.56 (95% IC: 0.28–0.75), *p* = 0.0004 and R = 0.51 (95% IC 0.22–0.72), *p* = 0.0016, Fig. 1B,C). Whereas s-GFAP was also correlated with age, disease duration and disease type, s-NfL was correlated with age and disease type. After adjustment for age, the levels of the 2 biomarkers were not independently correlated with EDSS level (either in RRMS group or in PPMS group) and treatment (not shown).

PPMS patients had higher s-GFAP and s-NfL levels than RRMS patients. After multivariate analysis including age and disease duration, s-GFAP (but not s-NfL) remained significantly higher in PPMS (Fig. 1D,E).

In the RRMS group, the presence of a recent relapse was correlated with lower s-GFAP but this association was not significant after adjustment for disease duration. S-NfL were similar in active and inactive patients.
<table><caption>**Table 1.** Characteristics of the patients. PPMS Primary progressive multiple sclerosis; RRMS relapsing remitting multiple sclerosis; EDSS expanded disability status scale; DMT disease modifying therapy; GFAP glial fibrillary acid protein; NfL neurofilament light chain; WM white matter; GM grey matter; NA not available. *Covariables were age and disease duration. †Covariables were log GFAP, age and disease duration.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">Whole group (n=129)</th><th rowspan="2">PPMS (n=18)</th><th rowspan="2">RRMS (n=111)</th><th rowspan="2">p-value<br>PPMS versus RRMS<br>(raw/adjusted)</th><th colspan="2">RRMS patients</th><th rowspan="2">p-value (active vs<br>inactive RRMS)</th></tr><tr><th>Active (n=18)</th><th>Inactive (n=93)</th></tr></thead><tbody><tr><td>No. of females (%)</td><td>75.2%</td><td>77.8%</td><td>74.8%</td><td>1</td><td>50%</td><td>79.6%</td><td>0.067</td></tr><tr><td>Age, years (mean ± SD)</td><td>41.5 ± 11</td><td>50.8 ± 7.2</td><td>39.9 ± 10.8</td><td>0.0001</td><td>35.3 ± 9.1</td><td>37.7 ± 10.8</td><td>0.473</td></tr><tr><td>Age at MS onset, years<br>(mean ± SD)</td><td>34.3 ± 11.2</td><td>46.9 ± 7.3</td><td>32.3 ± 10.5</td><td>&lt;0.0001</td><td>33.6 ± 10</td><td>32.1 ± 10.5</td><td>0.603</td></tr><tr><td>Disease duration, months<br>(mean ± SD)</td><td>80 ± 86</td><td>42 ± 15</td><td>86 ± 90</td><td>0.28</td><td>20 ± 62</td><td>98 ± 60</td><td>&lt;0.0001</td></tr><tr><td>EDSS, median, IQR</td><td>1.75 (0.0; 3.0)</td><td>3.5 (2.0; 6.0)</td><td>1.0 (0.0; 3.0)</td><td>&lt;0.0001</td><td>1.5 (1.0; 2.0)</td><td>1.0 (0.0; 3.0)</td><td>0.736</td></tr><tr><td>Current DMT (%)</td><td>41.9%</td><td>None</td><td>48.7%</td><td>0.0001</td><td>5.6%</td><td>57%</td><td>0.0001</td></tr><tr><td colspan="8"><strong>Serum biomarkers (pg/ml)</strong></td></tr><tr><td>GFAP (mean ± SD)</td><td>89.9 ± 49</td><td>130.3 ± 72.8</td><td>83.4 ± 41.1</td><td>0.0032</td><td>63.3 ± 21.7</td><td>87.3 ± 43</td><td>0.015</td></tr><tr><td>Log GFAP</td><td>4.38 ± 0.48</td><td>4.73 ± 0.55</td><td>4.32 ± 0.44</td><td>0.0007/0.008*</td><td>4.08 ± 0.41</td><td>4.37 ± 0.43</td><td>0.015</td></tr><tr><td>NfL</td><td>9.93 ± 5.06</td><td>13.63 ± 6.60</td><td>9.33 ± 4.52</td><td>0.0016</td><td>8.95 ± 5.09</td><td>9.40 ± 4.43</td><td>0.64</td></tr><tr><td>Log NfL</td><td>2.18 ± 0.47</td><td>2.51 ± 0.48</td><td>2.13 ± 0.45</td><td>0.0014/0.40†</td><td>2.06 ± 0.53</td><td>2.15 ± 0.43</td><td>0.45</td></tr><tr><td>MRI volume (n)</td><td>(n=45)</td><td>(n=8)</td><td>(n=37)</td><td></td><td></td><td></td><td></td></tr><tr><td>T2 lesion load</td><td>14.03 ± 13.00</td><td>20.19 ± 17.40</td><td>12.70 ± 11.72</td><td>0.18</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>WM vol</td><td>424.03 ± 55.24</td><td>415.11 ± 50.96</td><td>425.96 ± 56.60</td><td>0.60</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>GM vol</td><td>662.95 ± 82.72</td><td>600.04 ± 46.8</td><td>679.64 ± 76.70</td><td>0.01</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Cortical GM vol</td><td>645.5 ± 76.04</td><td>581.9 ± 44.9</td><td>659.3 ± 74.7</td><td>0.005</td><td>NA</td><td>NA</td><td>NA</td></tr></tbody></table>

Lesion load and brain volume were analysed in 45 patients (37 RRMS). s-GFAP level correlated with white matter lesion load and inversely correlated with WM, GM and cortical GM volumes (Table 1, Fig. 1F–I)). s-NfL level was not correlated with MRI parameters.

Discussion

Our results, in line with 3 recent studies, suggest that s-GFAP is an additional serum biomarker of interest in the context of MS<sup>9-11</sup>. Indeed, we confirm, that s-GFAP and s-NfL, are higher in PPMS than in RRMS. Even if some studies (including CSF studies) disclosed contradictory results, s-NfL has been repeatedly demonstrated to be higher in PPMS than in stable RRMS patients<sup>3-6</sup>. We suggest that, partly due to the small size of our cohort, our study was underpowered to demonstrate a significant difference after adjustment. Moreover, the absence of correlation between biomarkers and EDSS was probably due to the relative benign disease severity of our cohort since most of the patients had RRMS with low EDSS (median EDSS value: 2.75, 83% with EDSS ≤ 3).

To date, mainly due to conflicting published results, it is unclear whether s-GFAP values are increased or decreased during relapses<sup>10,16-20</sup>. Our study, did not evidenced any significant difference of s-GFAP values in patients with and without recent relapses suggesting that larger cohorts are needed to identify any significant and meaningful difference. Moreover, were not able to confirm previous studies disclosing higher s-NfL level in patients with recent relapse. This was probably due to the small size of our cohort since only 18 patients had recent relapse. This was also probably caused by the 3-months period used to define a recent relapse since it has been shown that s-NfL steadily decrease from a pic at the time of a relapse to baseline levels approximately 3 months after the relapse<sup>21</sup>.

To date, apart from retrospective analysis of randomized control trials, only few studies have correlated serum biomarkers and MRI data in MS<sup>3-6</sup>. Most of these studies used semi-quantitative MRI assessment and/or had lower sample size than our study. Only one recent study disclosed an association between s-GFAP (T1 and T2) lesion load and cortical GM atrophy<sup>10</sup>. With respect to s-NfL, 4 studies mainly disclosed a positive association with T2 lesion load<sup>3-6</sup>. Our analysis in 45 inactive patients showed that s-GFAP is correlated with T2 lesions load and (negatively) with WM and GM volumes. S-NfL were not correlated with any of the MRI measurements. These discrepancies are probably explained by methodological issues and biases underlining that larger cohorts are needed to identify accurate correlations between serum biomarkers and MRI measures.

Our study has some limitations, notably its retrospective design as well as the small size and the relative benign disease severity of our cohort that limited our statistical power to identify significant associations.

Nevertheless, we suggest that s-GFAP is a potentially interesting marker to distinguish PPMS and RRMS. Whether or not it can be useful to distinguish, in combination with s-NfL, disease activity from disease progression remains to be further assessed in larger independent cohorts.
<figure><img src="image_3.png" /><figcaption>**Figure 1.** (A) S-GFAP and s-NfL levels are correlated in MS patients ($r=0.66, p=1e-06$). Serum and CSF GFAP (B) and NfL (C) were correlated ($r=0.58, p=1e-04$ and $r=0.48, p=0.0012$). s-GFAP (D) and s-NfL (E) levels are higher in PPMS than in RRMS (respectively $130.3 \pm 72.8$ vs $83.4 \pm 41.1$ pg/ml and $13.63$ pg/ml 6.60 vs. $9.33$ pg/ml 4.52 pg/ml). S-GFAP is correlated with white matter lesions volume ($F, r=0.39, p=0.0093$) and is negatively correlated with white matter ($G, r=-0.4, p=0.063$), grey matter ($H, r=-0.38, p=0.0093$) and cortical grey matter ($I, r=-0.37, p=0.0115$) volumes.</figcaption></figure>

Received: 11 November 2019; Accepted: 15 April 2020

Published online: 02 July 2020

References

1. Reich, D. S., Lucchinetti, C. F. & Calabresi, P. A. Multiple sclerosis. *N. Engl. J. Med.* **378**, 169–180 (2018).

2. Dubuisson, N., Puentes, F., Giovannoni, G. & Gnanapavan, S. Science is 1% inspiration and 99% biomarkers. *Mult. Scler. Houndmills Basingstoke Engl.* https://doi.org/10.1177/1352458517709362 (2017).

3. Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. *Ann. Neurol.* **81**, 857–870 (2017).

4. Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. *Neurology* **92**, e1007–e1015 (2019).

5. Siller, N. et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. *Mult. Scler. J.* https://doi.org/10.1177/1352458518765666 (2018).

6. Barro, C. et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. *Brain J. Neurol.* https://doi.org/10.1093/brain/awy154 (2018).

7. Cantó, E. et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. *JAMA Neurol.* https://doi.org/10.1001/jamaneurol.2019.2137 (2019).

8. Jakimovski, D. et al. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. *Ann. Clin. Transl. Neurol.* **6**, 1757–1770 (2019).

9. Abdelhak, A., Huss, A., Kassubek, J., Tumani, H. & Otto, M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. *Sci. Rep.* **8**, 14798 (2018).
10. Högel, H. et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. *Mult. Scler. Houndmills Basingstoke Engl.* https://doi.org/10.1177/1352458518819380 (2018).

11. Abdelhak, A. et al. Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?. *Front. Neurol.* **10**, 280 (2019).

12. Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* **17**, 162–173 (2018).

13. Fartaria, M. J. et al. Automated detection of white matter and cortical lesions in early stages of multiple sclerosis. *J. Magn. Reson. Imaging JMRI* **43**, 1445–1454 (2016).

14. Wu, Y. et al. Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI. *NeuroImage* **32**, 1205–1215 (2006).

15. Fartaria, M. J. et al. Partial volume-aware assessment of multiple sclerosis lesions. *NeuroImage Clin.* **18**, 245–253 (2018).

16. Norgren, N. et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. *Neurology* **63**, 1586–1590 (2004).

17. Burman, J. et al. Assessing tissue damage in multiple sclerosis: a biomarker approach. *Acta Neurol. Scand.* **130**, 81–89 (2014).

18. Watanabe, M. et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. *Neurology* **93**, e1299–e1311 (2019).

19. Mañé-Martínez, M. A. et al. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. *J. Neuroimmunol.* **299**, 112–117 (2016).

20. Martínez, M. A. M. et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. *Mult. Scler. J.* **21**, 550–561 (2015).

21. Bergman, J. et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. *Neurol. Immunol. Neuroinflammation* **3**, e271 (2016).

**Author contributions**

X.A., P.L. and S.L.: study concept. E.L.B., C.D., A.M.M., C.C.D., M.C., F.P., P.P., N.M., J.D., T.K., B.M., M.F., R.C.J.: data acquisition, data analysis, and interpretation. A.M.M., C.H. and S.L.: biomarkers assessment. X.A.: drafting of the manuscript. PL and SL: study supervision and critical revision. All authors critically reviewed and approved the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to X.A.

Reprints and permissions information is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_4.png" /></figure>

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020